TVTX Logo

Travere Therapeutics, Inc. (TVTX) 

NASDAQ
Market Cap
$1.6B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
742 of 774
Rank in Industry
411 of 432

Largest Insider Buys in Sector

TVTX Stock Price History Chart

TVTX Stock Performance

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola …

Insider Activity of Travere Therapeutics, Inc.

Over the last 12 months, insiders at Travere Therapeutics, Inc. have bought $0 and sold $2.11M worth of Travere Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Travere Therapeutics, Inc. have bought $0 and sold $3.19M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $178,500 was made by ASELAGE STEVE (Chief Executive Officer) on 2017‑06‑14.

List of Insider Buy and Sell Transactions, Travere Therapeutics, Inc.

2024-10-04Saledirector
40,000
0.0512%
$14.73$589,101+16.48%
2024-09-30Saledirector
40,000
0.0489%
$14.06$562,324+26.34%
2024-09-10SaleCHIEF MEDICAL OFFICER
684
0.0009%
$12.98$8,878+35.28%
2024-09-09SaleCHIEF EXECUTIVE OFFICER
21,125
0.0247%
$11.52$243,360+34.53%
2024-09-09SaleCHIEF COMMERCIAL OFFICER
2,191
0.0026%
$11.52$25,240+34.53%
2024-09-09SaleSENIOR VICE PRESIDENT, R&D
4,387
0.0051%
$11.52$50,538+34.53%
2024-09-09SaleSVP, GC & CORPORATE SECRETARY
4,387
0.0051%
$11.52$50,538+34.53%
2024-09-09SaleCHIEF FINANCIAL OFFICER
2,490
0.0029%
$11.52$28,685+34.53%
2024-09-09SaleCHIEF MEDICAL OFFICER
2,191
0.0026%
$11.52$25,240+34.53%
2024-09-04SaleCHIEF FINANCIAL OFFICER
514
0.0006%
$9.51$4,888+66.77%
2024-04-11SaleCHIEF FINANCIAL OFFICER
54
<0.0001%
$6.74$364+33.43%
2024-02-01SaleCHIEF EXECUTIVE OFFICER
19,122
0.0247%
$8.70$166,435-4.36%
2024-02-01SaleCHIEF COMMERCIAL OFFICER
4,195
0.0053%
$8.53$35,789-4.36%
2024-02-01SaleSENIOR VICE PRESIDENT, R&D
4,764
0.0062%
$8.71$41,495-4.36%
2024-02-01SaleSVP, GC & CORPORATE SECRETARY
4,764
0.0062%
$8.71$41,495-4.36%
2024-02-01SaleCHIEF FINANCIAL OFFICER
3,818
0.0048%
$8.53$32,573-4.36%
2024-02-01SaleCHIEF MEDICAL OFFICER
2,174
0.0028%
$8.53$18,547-4.36%
2024-02-01SaleSVP, CHIEF ACCOUNTING OFFICER
2,820
0.0036%
$8.53$24,058-4.36%
2024-01-23SaleCHIEF EXECUTIVE OFFICER
7,873
0.0101%
$8.96$70,542-10.24%
2024-01-23SaleCHIEF COMMERCIAL OFFICER
1,559
0.002%
$9.07$14,138-10.24%

Insider Historical Profitability

49.75%
Meckler Jeffrey Adirector
81000
0.0931%
$18.3431+66.46%
Shkreli Martin
1765168
2.0281%
$18.34398+21.5%
ASELAGE STEVE
146919
0.1688%
$18.34437+123.45%
Richardson Steven Garydirector
129165
0.1484%
$18.3430+123.82%
PANOFF MARC LChief Financial Officer
121100
0.1391%
$18.3410+138.48%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$60.11M10.247.8M-1.53%-$933,634.74<0.01
Armistice Capital Llc$57.83M9.857.5M+1.57%+$894,360.000.19
Deep Track Capital Lp$56.82M9.687.37M0%+$00.26
State Street$50.95M8.686.61M+23.47%+$9.69M<0.01
The Vanguard Group$48.31M8.236.27M+13.61%+$5.79M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.